
Sign up to save your podcasts
Or
So, this trial might appear a bit boring and maybe not so relevant – but maybe only at first. What might add to the difficulty reading or interpreting it is the non-inferiority design – and we might to a methods primer on that in the future. However, this trial may be the answer for a very important question: what do we do with patients who are intolerant to higher doses of statins – can a statin-sparing regimen be the answer?
This was a randomized controlled trial of a high-intensity statin, rosuvastatin 20mg daily vs a moderate-intensity statin – 10mg of rosuvastatin daily – plus 10mg of ezetimibe or Zetia. The trial recruited 3,780 patients with atherosclerotic cardiovascular disease and followed them for three years. The primary endpoint was the composite of cardiovascular death, major adverse cardiovascular events, or non-fatal stroke, and was reached in 9.9% in the high-intensity statin group vs 9.1% in the combination group.
Our guest is Christopher P. Cannon, M.D. He is a cardiologist at Brigham and Women’s Hospital in Boston and a professor at Harvard Medical School. He has run major trials of statins and other interventions to prevent major adverse cardiovascular (and cerebrovascular) events, including the IMPROVE-IT study.
References:
Subscribe to our YouTube Channel and mailing list: https://linktr.ee/imjournalclub
Hosted on Acast. See acast.com/privacy for more information.
So, this trial might appear a bit boring and maybe not so relevant – but maybe only at first. What might add to the difficulty reading or interpreting it is the non-inferiority design – and we might to a methods primer on that in the future. However, this trial may be the answer for a very important question: what do we do with patients who are intolerant to higher doses of statins – can a statin-sparing regimen be the answer?
This was a randomized controlled trial of a high-intensity statin, rosuvastatin 20mg daily vs a moderate-intensity statin – 10mg of rosuvastatin daily – plus 10mg of ezetimibe or Zetia. The trial recruited 3,780 patients with atherosclerotic cardiovascular disease and followed them for three years. The primary endpoint was the composite of cardiovascular death, major adverse cardiovascular events, or non-fatal stroke, and was reached in 9.9% in the high-intensity statin group vs 9.1% in the combination group.
Our guest is Christopher P. Cannon, M.D. He is a cardiologist at Brigham and Women’s Hospital in Boston and a professor at Harvard Medical School. He has run major trials of statins and other interventions to prevent major adverse cardiovascular (and cerebrovascular) events, including the IMPROVE-IT study.
References:
Subscribe to our YouTube Channel and mailing list: https://linktr.ee/imjournalclub
Hosted on Acast. See acast.com/privacy for more information.